Global release

ASDS release
21 . 10 .2024
Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
  • Global release
EADV 2024 Late Breakers
25 . 09 .2024
Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations
  • Global release
EADV 2024
17 . 09 .2024
Press release
Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024
  • Global release
Galderma logo black thumbnail
29 . 08 .2024
Press release
Galderma successfully issued an inaugural CHF 500 million bond
  • Global release
25 . 07 .2024
Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance
  • Global release
Uppsala
19 . 06 .2024
Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence
  • Global release
Restylane Volyme Pack shot
23 . 05 .2024
Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets
  • Global release
Nemo access consortium
07 . 05 .2024
Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries
  • Global release
Galderma logo
21 . 03 .2024
Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow
  • Global release
AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio
19 . 03 .2024
Press release
AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio
  • Global release